|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar
|
|
4
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar
|
|
6
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar
|
|
7
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar
|
|
8
|
Wang S, Cang S and Liu D: Third-generation
inhibitors targeting EGFR T790M mutation in advanced non-small cell
lung cancer. J Hematol Oncol. 9:342016. View Article : Google Scholar
|
|
9
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar
|
|
10
|
Leighl NB, Rekhtman N, Biermann WA, Huang
J, Mino-Kenudson M, Ramalingam SS, West H, Whitlock S and
Somerfield MR: Molecular testing for selection of patients with
lung cancer for epidermal growth factor receptor and anaplastic
lymphoma kinase tyrosine kinase inhibitors: American Society of
Clinical Oncology endorsement of the College of American
Pathologists/International Association for the study of lung
cancer/association for molecular pathology guideline. J Clin Oncol.
32:3673–3679. 2014. View Article : Google Scholar
|
|
11
|
Smouse JH, Cibas ES, Jänne PA, Joshi VA,
Zou KH and Lindeman NI: EGFR mutations are detected comparably in
cytologic and surgical pathology specimens of nonsmall cell lung
cancer. Cancer. 117:67–72. 2009.
|
|
12
|
Reynolds JP, Tubbs RR, Minca EC, MacNamara
S, Almeida FA, Ma PC, Pennell NA and Cicenia JC: EGFR mutational
genotyping of liquid based cytology samples obtained via fine
needle aspiration (FNA) at endobronchial ultrasound of non-small
cell lung cancer (NSCLC). Lung Cancer. 86:158–163. 2014. View Article : Google Scholar
|
|
13
|
Lozano MD, Labiano T, Echeveste J, Gurpide
A, Martín-Algarra S, Zhang G, Sharma A and Palma JF: Assessment of
EGFR and KRAS mutation status from FNAs and core-needle biopsies of
non-small cell lung cancer. Cancer Cytopathol. 123:230–236. 2015.
View Article : Google Scholar
|
|
14
|
Malapelle U, Sirera R, Jantus-Lewintre E,
Reclusa P, Calabuig-Fariñas S, Blasco A, Pisapia P, Rolfo C and
Camps C: Profile of the Roche cobas® EGFR mutation test
v2 for non-small cell lung cancer. Expert Rev Mol Diagn.
17:209–215. 2017. View Article : Google Scholar
|
|
15
|
Marchetti A, Del Grammastro M, Felicioni
L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A,
Brandes AA, et al: Assessment of EGFR mutations in circulating
tumor cell preparations from NSCLC patients by next generation
sequencing: Toward a real-time liquid biopsy for treatment. PLoS
One. 9:e1038832014. View Article : Google Scholar
|
|
16
|
Remon J, Caramella C, Jovelet C, Lacroix
L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, et
al: Osimertinib benefit in EGFR-mutant NSCLC patients with
T790M-mutation detected by circulating tumour DNA. Ann Oncol.
28:784–790. 2017.
|
|
17
|
Sacher AG, Paweletz C, Dahlberg SE, Alden
RS, O’Connell A, Feeney N, Mach SL, Jänne PA and Oxnard GR:
Prospective validation of rapid plasma genotyping for the detection
of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol.
2:1014–1022. 2016. View Article : Google Scholar
|
|
18
|
Sacher AG, Komatsubara KM and Oxnard GR:
Application of plasma genotyping technologies in non-small cell
lung cancer: A practical review. J Thorac Oncol. 12:1344–1356.
2017. View Article : Google Scholar
|
|
19
|
Huang WL, Chen YL, Yang SC, Ho CL, Wei F,
Wong DT, Su WC and Lin CC: Liquid biopsy genotyping in lung cancer:
Ready for clinical utility? Oncotarget. 8:18590–18608. 2017.
|
|
20
|
Asaka S, Yoshizawa A, Matsuda K, Yamaguchi
A, Yamamoto H, Shiina T, Nakata R, Ogawa K, Zhang M and Honda T: A
novel, rapid point-of-care test for lung cancer patients to detect
epidermal growth factor receptor gene mutations by using real-time
droplet-PCR and fresh liquid cytology specimens. Oncol Rep.
37:1020–1026. 2017. View Article : Google Scholar
|
|
21
|
Layfield LJ, Baloch Z, Elsheikh T, Litzky
L, Rekhtman N, Travis WD, Zakowski M, Zarka M and Geisinger K:
Standardized terminology and nomenclature for respiratory cytology:
The Papanicolaou Society of Cytopathology guidelines. Diagn
Cytopathol. 44:399–409. 2016. View Article : Google Scholar
|
|
22
|
Vallée A, Le Loupp AG and Denis MG:
Efficiency of the Therascreen® RGQ PCR kit for the
detection of EGFR mutations in non-small cell lung carcinomas. Clin
Chim Acta. 429:8–11. 2014. View Article : Google Scholar
|
|
23
|
Landis JR and Koch GG: The measurement of
observer agreement for categorical data. Biometrics. 33:159–174.
1977. View Article : Google Scholar
|
|
24
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: International Union Against Cancer (UICC) TNM Classification of
Malignant Tumours. 7th edition. Wiley-Blackwell; Oxford: 2009
|
|
25
|
Gravitz L: Therapy: This time it’s
personal. Nature. 509:S52–S54. 2014. View Article : Google Scholar
|
|
26
|
Soo RA, Stone ECA, Cummings KM, Jett JR,
Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S,
et al: Scientific advances in thoracic oncology 2016. J Thorac
Oncol. 12:1183–1209. 2017. View Article : Google Scholar
|
|
27
|
Doble B, John T, Thomas D, Fellowes A, Fox
S and Lorgelly P: Cost-effectiveness of precision medicine in the
fourth-line treatment of metastatic lung adenocarcinoma: An early
decision analytic model of multiplex targeted sequencing. Lung
Cancer. 107:22–35. 2017. View Article : Google Scholar
|
|
28
|
Harada S, Arend R, Dai Q, Levesque JA,
Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, et al:
Implementation and utilization of the molecular tumor board to
guide precision medicine. Oncotarget. 8:57845–57854. 2017.
View Article : Google Scholar
|
|
29
|
Suzuki N, Kamataki A, Yamaki J and Homma
Y: Characterization of circulating DNA in healthy human plasma.
Clin Chim Acta. 387:55–58. 2008. View Article : Google Scholar
|
|
30
|
Li CN, Hsu HL, Wu TL, Tsao KC, Sun CF and
Wu JT: Cell-free DNA is released from tumor cells upon cell death:
A study of tissue cultures of tumor cell lines. J Clin Lab Anal.
17:103–107. 2003. View Article : Google Scholar
|
|
31
|
Jahr S, Hentze H, Englisch S, Hardt D,
Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood
plasma of cancer patients: Quantitations and evidence for their
origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665.
2001.
|
|
32
|
Asaka S, Yoshizawa A, Nakata R, Negishi T,
Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y and Honda
T: Utility of bronchial lavage fluids for epithelial growth factor
receptor mutation assay in lung cancer patients: Comparison between
cell pellets, cell blocks and matching tissue specimens. Oncol
Lett. 15:1469–1474. 2018.
|
|
33
|
Asano H, Toyooka S, Tokumo M, Ichimura K,
Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, et al:
Detection of EGFR gene mutation in lung cancer by mutant-enriched
polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006.
View Article : Google Scholar
|
|
34
|
Soh J, Toyooka S, Aoe K, Asano H, Ichihara
S, Katayama H, Hiraki A, Kiura K, Aoe M, Sano Y, et al: Usefulness
of EGFR mutation screening in pleural fluid to predict the clinical
outcome of gefitinib treated patients with lung cancer. Int J
Cancer. 119:2353–2358. 2006. View Article : Google Scholar
|
|
35
|
Kimura H, Fujiwara Y, Sone T, Kunitoh H,
Tamura T, Kasahara K and Nishio K: EGFR mutation status in
tumour-derived DNA from pleural effusion fluid is a practical basis
for predicting the response to gefitinib. Br J Cancer.
95:1390–1395. 2006. View Article : Google Scholar
|
|
36
|
Lin J, Gu Y, Du R, Deng M, Lu Y and Ding
Y: Detection of EGFR mutation in supernatant, cell pellets of
pleural effusion and tumor tissues from non-small cell lung cancer
patients by high resolution melting analysis and sequencing. Int J
Clin Exp Pathol. 7:8813–8822. 2014.
|
|
37
|
Kawahara A, Fukumitsu C, Taira T, Abe H,
Takase Y, Murata K, Yamaguchi T, Azuma K, Ishii H, Takamori S, et
al: Epidermal growth factor receptor mutation status in cell-free
DNA supernatant of bronchial washings and brushings. Cancer
Cytopathol. 123:620–628. 2015. View Article : Google Scholar
|
|
38
|
Park S, Hur JY, Lee KY, Lee JC, Rho JK,
Shin SH and Choi CM: Assessment of EGFR mutation status using
cell-free DNA from bronchoalveolar lavage fluid. Clin Chem Lab Med.
55:1489–1495. 2017. View Article : Google Scholar
|
|
39
|
Mitsudomi T, Kosaka T and Yatabe Y:
Biological and clinical implications of EGFR mutations in lung
cancer. Int J Clin Oncol. 11:190–198. 2006. View Article : Google Scholar
|
|
40
|
Naidoo J, Sima CS, Rodriguez K, Busby N,
Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME and Yu HA:
Epidermal growth factor receptor exon 20 insertions in advanced
lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Cancer. 121:3212–3220. 2015. View Article : Google Scholar
|
|
41
|
Lee VH, Tin VP, Choy TS, Lam KO, Choi CW,
Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, et al: Association of
exon 19 and 21 EGFR mutation patterns with treatment outcome after
first-line tyrosine kinase inhibitor in metastatic non-small-cell
lung cancer. J Thorac Oncol. 8:1148–1155. 2013. View Article : Google Scholar
|
|
42
|
Dedhia P, Tarale S, Dhongde G, Khadapkar R
and Das B: Evaluation of DNA extraction methods and real time PCR
optimization on formalin-fixed paraffin-embedded tissues. Asian Pac
J Cancer Prev. 8:55–59. 2007.
|
|
43
|
Harada S, Agosto-Arroyo E, Levesque JA,
Alston E, Janowski KM, Coshatt GM and Eltoum IA: Poor cell block
adequacy rate for molecular testing improved with the addition of
Diff-Quik-stained smears: Need for better cell block processing.
Cancer Cytopathol. 123:480–487. 2015. View Article : Google Scholar
|
|
44
|
Uchibori K, Inase N, Araki M, Kamada M,
Sato S, Okuno Y, Fujita N and Katayama R: Brigatinib combined with
anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated
non-small-cell lung cancer. Nat Commun. 8:147682017. View Article : Google Scholar
|
